missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Mouse anti-Canine IgE Secondary Antibody
Mouse Monoclonal Secondary Antibody
Marque: Invitrogen™ MA516652
Les retours ne sont pas autorisés pour ce produit.
Afficher la politique du retour.
Description
This antibody recognizes canine IgE, and does not cross react with canine IgM, IgA, IgG1 or IgG2. Western blot analysis against affinity purified IgE shows a single major band of 62-65kDa under reducing conditions.
Anti-Canine secondary antibodies are affinity-purified antibodies with well-characterized specificity for canine (dog) immunoglobulins and are useful in the detection, sorting or purification of its specified target. Secondary antibodies offer increased versatility enabling users to use many detection systems (e.g. HRP, AP, fluorescence). They can also provide greater sensitivity through signal amplification as multiple secondary antibodies can bind to a single primary antibody. Most commonly, secondary antibodies are generated by immunizing the host animal with a pooled population of immunoglobulins from the target species and can be further purified and modified (i.e. immunoaffinity chromatography, antibody fragmentation, label conjugation, etc.) to generate highly specific reagents.
Spécification
Canine IgE | |
Monoclonal | |
1 mg/mL | |
PBS with <0.1% sodium azide | |
Affinity purified IgE preparation from heavily parasitized and allergic dog serum. | |
250 μg | |
Secondary | |
Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles. | |
Liquid |
ELISA, Western Blot | |
E6-2A1 | |
Unconjugated | |
Mouse | |
Protein A | |
RUO | |
Canine | |
Secondary Antibody | |
IgG2a |
Suggestions de produits
Clients qui ont consulté cet article ont également consulté
Viewing 1-4 of
Correction du contenu d'un produit
Veuillez fournir vos retours sur le contenu du produit en remplissant le formulaire ci-dessous.
Nom du produit
Invitrogen™ Mouse anti-Canine IgE Secondary Antibody > 250 μg; Unconjugated
Vous avez repéré une opportunité d'amélioration ?Partager une correction de contenu